Skip to main content
. 2024 Sep 12;14:372. doi: 10.1038/s41398-024-03059-8

Fig. 3. Evidence for maintained subjective quality of the psychedelic experience when psilocybin is administered with midazolam.

Fig. 3

A Time course of subjective quality of the psychedelic experience, plotted as Altered States of Consciousness (ASC) questionnaire scores averaged across questions and participants. Black symbols: all participants. Blue and red symbols: low and high midazolam (Midaz) dose, respectively (n = 4 for each dose range). Score range for the ASC is 0 to 100. B Scores on each question averaged across participants receiving low (top) and high (bottom) midazolam doses. C ASC scores on dosing day for each participant as a function of midazolam dose. Symbols show average of the maximum score on each question during the dosing session for each participant. Grey rectangles represent median and interquartile range for normative data for psilocybin alone (median = 55) [26] and for placebo (median = 3) [56]. The two participants who exhibited memory impairment in Fig. 4 are indicated by filled symbols. D Comparison of dosing-day responses on the ASC to normative data set [26]. Error bars display mean +/− SEM. See Supplementary Table 5 for full text of ASC questions.